Q2 2023

Filed Oct 23, 2025 · 10-Q · 846 days after period end · 0001493152-25-019037

Q2 2023 · 10-Q

Revenue—

Net Income

-$279.25K

N/M vs Q2 2022

EPS Diluted

$0.00

— vs Q2 2022

Operating Cash Flowderived-$186,841N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	—	$28.43K	$30.46K	$6.24K
Net Income	-$279.25K	-$645.80K	$3.36M	-$1.51M
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR